MBRX News

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Moleculin Announces New Annamycin Collaboration in Brain Tumors

Moleculin to Participate in the Virtual Investor Closing Bell Series

Moleculin Announces Reverse Stock Split

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin